Literature DB >> 16088379

Expression of versican in relation to chondrogenesis-related extracellular matrix components in canine mammary tumors.

I Erdélyi1, A J A M van Asten, J E van Dijk, H Nederbragt.   

Abstract

Versican plays a role in tumor cell proliferation and adhesion and may also regulate cell phenotype. Furthermore, it is one of the pivotal proteoglycans in mesenchymal condensation during prechondrogenesis. We have previously demonstrated accumulation of versican protein in myoepithelial-like spindle cell proliferations and myxoid tissues of complex and mixed mammary tumors of dogs. The objective of this study was to investigate whether the high expression of versican relates to prechondrogenesis in these tissues. Therefore, we aimed to identify cartilage markers, such as collagen type II and aggrecan both at mRNA and protein level in relation to versican. The neopitope of chondoitin-6-sulphate (3B3) known to be generated in developing cartilage has been investigated by immunohistochemisty and a panel of antibodies were used to characterize the phenotype of cells that are involved in cartilage formation. In addition, co-localization of versican with hyaluronan and link protein was studied. RT-PCR revealed upregulation of genes of versican, collagen type II and aggrecan in neoplastic tissues, especially in complex and mixed tumors. Immunohistochemistry showed the expression of cartilage biomarkers not only in the cartilagenous tissues of mixed tumors, but also in myoepitheliomas and in the myoepithelial-like cell proliferations and myxoid areas of complex and mixed tumors. The results show the cartilagenous differentiation of complex tumors and myoepitheliomas and indicate that the myxoid tissues and myoepithelial-like cell proliferations are the precursor tissues of the ectopic cartilage in mixed tumors. Furthermore, we suggest that cartilage formation in canine mammary tumors is a result of (myo)epithelial to mesenchymal transition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088379     DOI: 10.1007/s00418-005-0007-y

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  45 in total

1.  Histochemical localisation of versican, aggrecan and hyaluronan in the developing condylar cartilage of the fetal rat mandible.

Authors:  S Shibata; K Fukada; S Suzuki; T Ogawa; Y Yamashita
Journal:  J Anat       Date:  2001-02       Impact factor: 2.610

2.  Hyaluronate binding properties of versican.

Authors:  R G LeBaron; D R Zimmermann; E Ruoslahti
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

3.  Aggrecan-versican-neurocan family proteoglycans.

Authors:  R U Margolis; R K Margolis
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.

Authors:  C Ricciardelli; K Mayne; P J Sykes; W A Raymond; K McCaul; V R Marshall; D J Horsfall
Journal:  Clin Cancer Res       Date:  1998-04       Impact factor: 12.531

5.  Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas.

Authors:  Thomas Aigner; Susanna Müller; Daniel Neureiter; Duane M Illstrup; Thomas Kirchner; Johannes Björnsson
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

6.  Developmental role of hyaluronate.

Authors:  B P Toole
Journal:  Connect Tissue Res       Date:  1982       Impact factor: 3.417

7.  Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican.

Authors:  Y Nara; Y Kato; Y Torii; Y Tsuji; S Nakagaki; S Goto; H Isobe; N Nakashima; J Takeuchi
Journal:  Histochem J       Date:  1997-01

8.  Immunohistochemical evaluation of versican, in relation to chondroitin sulphate, in canine mammary tumours.

Authors:  I Erdélyi; D H M Nieskens; J E Van Dijk; L Vass; H Nederbragt
Journal:  Histol Histopathol       Date:  2003-10       Impact factor: 2.303

9.  Versican modulates embryonic chondrocyte morphology via the epidermal growth factor-like motifs in G3.

Authors:  Y Zhang; Y Wu; L Cao; V Lee; L Chen; Z Lin; C Kiani; M E Adams; B B Yang
Journal:  Exp Cell Res       Date:  2001-02-01       Impact factor: 3.905

10.  A large chondroitin sulfate proteoglycan (PG-M) synthesized before chondrogenesis in the limb bud of chick embryo.

Authors:  K Kimata; Y Oike; K Tani; T Shinomura; M Yamagata; M Uritani; S Suzuki
Journal:  J Biol Chem       Date:  1986-10-15       Impact factor: 5.157

View more
  7 in total

Review 1.  Recent progress in histochemistry and cell biology: the state of the art 2005.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2005-11-11       Impact factor: 4.304

Review 2.  The histochemistry and cell biology vade mecum: a review of 2005-2006.

Authors:  Douglas J Taatjes; Christian Zuber; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2006-11-24       Impact factor: 4.304

3.  Increased expression of chondroitin sulphate proteoglycans in rat hepatocellular carcinoma tissues.

Authors:  Xiao-Li Jia; Si-Yuan Li; Shuang-Suo Dang; Yan-An Cheng; Xin Zhang; Wen-Jun Wang; Clare E Hughes; Bruce Caterson
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

4.  HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland.

Authors:  Karine Araújo Damasceno; Enio Ferreira; Alessandra Estrela-Lima; Conrado de Oliveira Gamba; Fernanda Freitas Miranda; Mariana Rezende Alves; Rafael Malagoli Rocha; André Luís Branco de Barros; Geovanni Dantas Cassali
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

5.  Versican expression in canine carcinomas in benign mixed tumours: is there an association with clinical pathological factors, invasion and overall survival?

Authors:  Karine A Damasceno; Angélica C Bertagnolli; Alessandra Estrela-Lima; Lorena Gr Ribeiro; Bruna S Rabelo; Cecília B Campos; André Lb Barros; Geovanni D Cassali
Journal:  BMC Vet Res       Date:  2012-10-20       Impact factor: 2.741

6.  Canine mammary mixed tumours: a review.

Authors:  Geovanni Dantas Cassali; Angélica Cavalheiro Bertagnolli; Enio Ferreira; Karine Araújo Damasceno; Conrado de Oliveira Gamba; Cecília Bonolo de Campos
Journal:  Vet Med Int       Date:  2012-10-21

7.  The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis.

Authors:  Albert J M Yee; Margarete Akens; Bing L Yang; Joel Finkelstein; Peng-Sheng Zheng; Zhaoqiong Deng; Burton Yang
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.